1390645-39-2

Basic information

• Product Name: N-benzyl-1-([2'-(1-triphenylmethyltetrazol-5-yl)-(1,1'-biphenyl)-4-yl]methyl)-4-methyl-2-n-propyl-1H-benzimidazole-6-carboxamide
• Synonyms: N-benzyl-1-([2'-(1-triphenylmethyltetrazol-5-yl)-(1,1'-biphenyl)-4-yl]methyl)-4-methyl-2-n-propyl-1H-benzimidazole-6-carboxamide
• CAS NO: 1390645-39-2
• Molecular Weight: 783.976
• Mol File: 1390645-39-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-benzyl-1-([2'-(1-triphenylmethyltetrazol-5-yl)-(1,1'-biphenyl)-4-yl]methyl)-4-methyl-2-n-propyl-1H-benzimidazole-6-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-benzyl-1-([2'-(1-triphenylmethyltetrazol-5-yl)-(1,1'-biphenyl)-4-yl]methyl)-4-methyl-2-n-propyl-1H-benzimidazole-6-carboxamide(1390645-39-2)
• EPA Substance Registry System: N-benzyl-1-([2'-(1-triphenylmethyltetrazol-5-yl)-(1,1'-biphenyl)-4-yl]methyl)-4-methyl-2-n-propyl-1H-benzimidazole-6-carboxamide(1390645-39-2)

Safety Data

• Hazardous Substances Data: 1390645-39-2(Hazardous Substances Data)

Upstream product

• 152628-03-0 4-methyl-2-n-propyl-1H-benzimidazole-6-carboxylic acid 
• 1239196-56-5 N-benzyl-4-methyl-2-n-propyl-1H-benzimidazole-6-carboxamide 
• 124750-51-2 N-(triephenylmethyl)-5-<4'-(bromomethyl)-biphenyl-2-yl>tetrazole 

Downstream Products

• 1390645-30-3 N-benzyl-1-([2'-(1H-tetrazol-5-yl)-(1,1'-biphenyl)-4-yl]methyl)-4-methyl-2-n-propyl-1H-benzimidazole-6-carboxamide 

Relevant articles and documents

Design, synthesis and biological activity of 6-substituted carbamoyl benzimidazoles as new nonpeptidic angiotensin II AT1 receptor antagonists

A series of 6-substituted carbamoyl benzimidazoles were designed and synthesised as new nonpeptidic angiotensin II AT1 receptor antagonists. The preliminary pharmacological evaluation revealed a nanomolar AT1 receptor binding affinity for all compounds in the series, and a potent antagonistic activity in an isolated rabbit aortic strip functional assay for compounds 6f, 6g, 6h and 6k was also demonstrated. Furthermore, evaluation in spontaneous hypertensive rats and a preliminary toxicity evaluation showed that compound 6g is an orally active AT1 receptor antagonist with low toxicity.